Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 4UNKNOWN 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Nasopharyngeal Carcinoma 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

Epirubicin 4Paclitaxel 3Cyclophosphamide 3Carboplatin 3anlotinib 2Capecitabine 2pirarubicin 1lobaplatin 1eribulin 1Zoledronic Acid 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
UNKNOWN × Triple Negative Breast Neoplasms × anlotinib × Clear all
NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

ChineseAMS

Phase 2 Unknown
35 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

ChineseAMS

Phase 2 Unknown
100 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡